A heterogeneity among studies was highly significant for all outcomes for mHSPC after ADT, 4 which reflects the prognostic differences among the disease subgroups.
← all excerpts
Prognostic factors and treatment choice for stage IV, low-volume metastasis hormone-sensitive prostate cancer: cross-sectional study of real-world data.
1
—
—